Wij willen met u aan tafel zitten en in een openhartig gesprek uitvinden welke uitdagingen en vragen er bij u spelen om zo, gezamelijk, tot een beste oplossing te komen. Oftewel, hoe kan de techniek u ondersteunen in plaats van dat u de techniek moet ondersteunen.

Echoing much of the existing data and research on the subject, SF-based Color released data today showing that based on its own testing program, most individuals who test positive for COVID-19 display either mild or no symptoms, including even running a fever. The results, taken from Color’s own testing of over 30,000 people to date across its California testing stations, shows that despite continuing efforts underway across the U.S. to reopen local and state economies, widespread testing is still key to any true recovery program.

Color notes that 1.3 percent of the people who it has tested to date have received positive results for COVID-19, and says that among those, 78% reported only mild symptoms, or said they were asymptomatic, meaning they displayed no observable symptoms whatsoever. What’s more, only 12% had a fever of over 100 degrees, which is bad news for efforts to contain potential transmission of cases through the reopening through measures like temperature checks at workplaces and shared use facilities.

Color’s data matches up with recently released information from the WHO that indicated as many as 80% of individuals who test positive display either mild or no symptoms. Color also shared more specific information around what symptoms those who did report some said they had, with most saying they had a cough – though the most highly correlated reported symptom with an actual positive test result is loss of smell, making it a much better indicator of a positive test result than fever, for instance.

Other notable findings from Color’s testing to date, which includes testing San Francisco’s frontline essential workers in partnership with the city, include that most of those who test positive are young (68% are aged between 18 and 40) and that Latinx and Black communities showed much higher positive results on a per capita basis than either white or Asian populations. Color’s data in both these regards support results shared by other organizations and researchers, backing up concerns around who will be most negatively affected by any hasty and unconsidered reopening efforts.


TechCrunch

NASA’s renewed efforts to return to the Moon may be impacted by the COVID-19 pandemic, but works still proceeds on a number of projects related to the effort, including a series of hot-fire test of thrusters designed by NASA and partner Frontier Aerospace. These tests, more than 60 in total performed over the course of just 10 days, were performed under conditions designed to simulate what it would be like to use them in space, and provided key information that could lead to the verification of this thruster design for future use by NASA and its commercial partners.

The prototype thrusters are designed for use with small rockets, in space, delivering enough power for flight path adjustments or altitude changes. They’re designed to be as small and efficient as possible, while also meeting the requirements of landing spacecraft on the Moon, and their first likely use will be in Astrobotic’s Peregrine lunar lander, which is currently scheduled to fly on a Vulcan Centaur rocket in July 2021.

Peregrine is part of NASA’s Commercial Lunar Payload Services (CLPS) program, through which the agency has built a list of what amount to approved vendors for building and flying lunar landers that can carry payloads to the Moon on its behalf. These thrusters are being developed under a separate program, NASA’s Thruster for the Advancement of Low-temperature Operation in Space (TALOS) project, but their work will contribute both to CLPS, and to future spacecraft used in NASA’s Artemis series of lunar missions.

The design of the thrusters incorporates use of a propellant made up of nitrogen and mono methyl hydrazine, which offers benefits like being able to burn at much lower temperatures without risk of freezing – their operating range is between -40 and 80 degrees Fahrenheit, whereas most traditional thrusters work at between 45 and 70 Fahrenheit. Their operating range has the side-benefit of not requiring conditioning hardware, which means that they can work with less bulky and power-hungry designs – both incredibly important when you’re building spacecraft.


TechCrunch

While a number of companies who currently offer at-home medical and health diagnostics had rushed to produce kits that would allow for self sample collection by people who passed a screening and believed they might have contracted the new coronavirus, the U.S. Food and Drug Administration (FDA) has updated its Emergency Use Authorization guidelines to private labs that specifically bar the use of at-home sample collection. This means startups including Everlywell, Carbon Health and Nurx will have to immediately discontinue their testing programs in light of the clarified rules.

The FDA issued the updated guidance on March 21, and though some of the companies had already begun to ship their sample collection kits to people, and even begun to receive samples back to their diagnostic laboratory partners, even any samples in-hand will not be tested, and will instead be destroyed in order to compel with the FDA’s request. Carbon Health is continuing testing at its physical clinics, and notified TechCrunch of this update on Sunday evening, and an individual who ordered the Carbon Health test and sent back their sample provided the following email explaining the decision and what happens next:

We have been working hard to provide our patients every opportunity for COVID-19 testing and treatment, including exploring different avenues for testing.

This evening, we were notified by our lab partner, Curative Inc, that the 3/21/2020 FDA update for COVID-19 testing clarified that at-home sample collection is not covered under the EUA (U.S. Food and Drug Administration’s Emergency Use Authorization). Carbon Health is discontinuing distribution of the at-home sample collection kits effective immediately.

Based on this update by the FDA, we sincerely regret to inform you that you will not get a test result. If you have already shipped your kit back, the specimen will be destroyed by Curative, Inc using standard biohazard disposal. If you have not received your kit yet, please discard it upon receipt.

Please schedule an in-clinic visit at a Carbon Health clinic near you, if possible, to be tested using our traditional specimen collection by a clinician. The turn-around time for results is about 3-5 days from time of specimen collection.

Our goal was to facilitate at home specimen collection in order to keep patients safely in their homes while also providing another avenue for patients to be tested. This is a very dynamic time and we are working tirelessly to work with new partners to expand COVID-19 testing for our communities, as soon as possible. We are truly sorry for the frustration and inconvenience this has caused.

All three of the companies we spoke to that were working to distribute these tests had partnered with labs that were approved under the FDA emergency guidelines to perform COVID-19 diagnostics, and it was the understanding of all parties that at-home self collection via swab kits was included in the authorization. All three also said they were offering their tests at-cost, and seeking ways to defray even that cost to consumers through potential healthcare agency partnerships. Each also offered telehealth consultations for both the sample-gathering process, as well as for delivery of the results.

The FDA’s goal with its emergency use authorization is to enable testing without sticking to its usual qualification process, but it must always balance accuracy and safety. It did grant emergency use approval to Cepheid’s rapid point-of-care test last Friday, as well, which should expand availability of tests on-site in locations like hospitals and emergency medical care clinics, but this updated rule means that at-home tests will not, in the near-term, be a path towards expanding testing coverage in the U.S.

Another startup, Scanwell, has developed an in-home test that includes the diagnostics, using a serological test that looks for the presence of antibodies in a person’s blood. This is still pending FDA approval, and the company is seeking that under the emergency use authorization, with an anticipated approval process time of around six to eight weeks.


TechCrunch

Netflix is testing out a new feature that could mean you never have to stop watching, not even while you work – it’s a pop-out video player, similar to the one you may be used to from iOS and macOS for any website or app that supports Safari’s native video player. Basically, that means you can choose to ‘pop out’ the video and then reposition it anywhere on your screen for a picture-in-picture effect that remains visible over any other apps you might be using.

The streaming company told Engadget, which found this experimental feature, that it’s only a test, but you can see why this might be a useful feature for users. Netflix could offer this already to iOS and Mac users using built-in system tools, but because it uses is own player (in part likely for copyright protection), it instead has to build its own feature. The benefit of this is that it should be coming to both Windows PCs and Macs should it graduate from being an experiment to being a full-fledged product.


TechCrunch

Created by R the Company. Powered by SiteMuze.